Table of Contents
| << Previous Issue | 2025 (Vol: 2025, Issue: 9) | Next Issue >> |
- Section: Mergers & Acquisitions
-
AbbVie to Acquire Gilgamesh’s Psychedelic Depression Treatment for US$1.2 B
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Half-Year Review of 2025
- Section: Research & Development
-
Novartis Signs US$2.2 B Deal with Arrowhead Pharmaceuticals for RNAi Therapy
RSS